A deeper understanding of HSPC1 inhibitor-induced cellular changes is essential to drive forward research and development of this class of drug with the potential to simultaneously target many signalling pathways shown to be de-regulated in cancer. The gene discussed is HSP90AA1; the disease is cancer.